Potential drug-drug interactions among U.S. adults treated with nirmatrelvir/ritonavir: A cross-sectional study of the National Covid Cohort Collaborative (N3C).

ABSTRACT:

Study objective

To estimate the prevalence of potential moderate to severe drug-drug interactions (DDIs) involving nirmatrelvir/ritonavir, identify interacting medications, and evaluate risk factors associated with potential DDIs.

Design

Cross-sectional study.

Data source

Electronic health records from the National COVID Cohort Collaborative Enclave, one of the largest COVID-19 data resources in the United States.

Patients

Outpatients aged ≥18 years and started nirmatrelvir/ritonavir between December 23, 2021 and March 31, 2022.

Intervention

Nirmatrelvir/ritonavir.

Measurements

The outcome is potential moderate to severe DDIs, defined as starting interacting medications reported by National Institutes of Health 30 days before or 10 days after star

SUBMITTER: Xiao X 

PROVIDER: S-EPMC10838345 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature